Catalyst overview
Research summary
This catalyst tracks a Phase 2 update for Obexelimab (CD19xFcyRIIb) in Multiple sclerosis. The expected timing is based on the latest available company guidance and may change.
MoonStone trial. 11/12/24- Trial initiated. 10/27/25- Positive results reported, trial met primary endpoint. Report 24-wk data in Q1 2026. Initiate global Ph3 trial in SPMS in Q1 2026. 11/12/25:- MoonStone Ph2 RMS trial positive 12-week results; 24-week data expected Q1 2026. 02/09/26:- MoonStone Ph2 RMS trial 12- and 24-week data showed ~95% reduction in new GdE T1 lesions; safety consistent. 03/16/26:- PR No update. 05/13/26:- PR No update. 08/13/26:- PR No update.
Verification
Confirm timing and program details against the company announcement or filing.